The Lower Urinary Tract as a Drug Target: Storing and Voiding

One tract, two opposite jobs

Micturition is not one event — it is a switch between two stable states. For roughly 99% of the day the lower urinary tract is in storage mode: the bladder wall (the detrusor muscle) stays relaxed and expands to hold a rising volume at low pressure, while the outlet — the bladder neck and the urethral sphincters — stays firmly shut. Then, for a few controlled seconds, everything flips into voiding mode: the detrusor contracts, the outlet relaxes, and urine flows. A healthy tract is defined not by strength but by coordination — the outlet must open at the exact moment the bladder squeezes. Almost every lower-urinary-tract disorder is a failure of one of these two states, and almost every drug is an attempt to nudge the balance back toward the one that is failing.

The players and their receptors

Three muscles, three nerves, four receptors — memorise these and the drugs write themselves. The detrusor — the muscle of the bladder wall — is driven by the parasympathetic nerves (via pelvic splanchnic fibres) acting on M3 muscarinic receptors: acetylcholine here means "contract and void." The same detrusor also carries beta-3 adrenergic receptors that, when stimulated by circulating and local noradrenaline, tell it to "relax and keep storing." The bladder neck and the prostatic smooth muscle are the dynamic part of the outlet, held shut by the sympathetic nerves acting on alpha-1 adrenergic receptors — this is the tone that resists flow. Finally the external urethral sphincter is skeletal muscle under somatic (voluntary) control through the pudendal nerve at nicotinic receptors — the switch you consciously hold to "wait." This is applied autonomic pharmacology, and it rewards a detour back to the Autonomic Nervous System chapter, where the muscarinic, alpha-1 and beta-3 receptors are taught from first principles.

Storage symptoms vs voiding symptoms

The patient's own words tell you which state has failed — and therefore which receptor to target. Symptoms cluster into two families that map cleanly onto the two states. Storage symptoms — urinary frequency, urgency, and nocturia (waking at night to void) — mean the bladder will not stay quiet during filling; the detrusor is misbehaving. Voiding (obstructive) symptoms — hesitancy, a weak or intermittent stream, straining, terminal dribble and a sense of incomplete emptying — mean the bladder cannot push urine out past a resistant outlet. This distinction is the single most useful thing at the bedside, because it points to entirely different drugs: storage complaints call for something that calms the detrusor, while voiding complaints call for something that relaxes or shrinks the outlet. The two men in the scene sit on opposite sides of this line.

Helping storage: the overactive bladder

When the problem is storage — the detrusor contracting uninvited during filling, producing urgency, frequency and urge incontinence — there are two rational moves, and both come straight off the diagram. First, block the accelerator: antimuscarinics such as oxybutynin, solifenacin and tolterodine block M3 receptors on the detrusor, damping the parasympathetic "contract" signal so the bladder stays quiet longer. Their limitation is selectivity — muscarinic receptors are everywhere, so the class-typical anticholinergic burden appears: dry mouth, constipation, blurred vision, and, importantly in older patients, confusion (cross-linking to the anticholinergic-burden warning in Principles of Pharmacology). Second, release the brake instead: mirabegron, a beta-3 adrenergic agonist, actively relaxes the detrusor to expand storage without touching muscarinic receptors — so it spares the dry-mouth/constipation profile, at the cost of watching blood pressure. The full clinical algorithm — first-line choice, bladder training, and where botulinum toxin fits — is the subject of the dedicated Overactive Bladder chapter.

Helping voiding: benign prostatic hyperplasia

When the problem is voiding — an ageing prostate obstructing the outlet, giving hesitancy, a weak stream and incomplete emptying — the strategy is to lower outlet resistance, and the prostate offers two separable targets. The obstruction has a dynamic component (the alpha-1-driven smooth-muscle tone of the bladder neck and prostate) and a static component (the sheer bulk of the enlarged gland). Attack the dynamic tone with an alpha-1 blocker: tamsulosin (relatively uroselective for the alpha-1A subtype concentrated in the prostate) relaxes that smooth muscle within days, easing the stream quickly. Attack the static bulk with a 5-alpha-reductase inhibitor: finasteride or dutasteride block conversion of testosterone to the more potent dihydrotestosterone (DHT) that drives prostatic growth, shrinking the gland over months. Alpha-blockers act fast but don't change the gland; 5-alpha-reductase inhibitors act slowly but actually reduce its size, so a large prostate is often treated with both. The full comparison — onset, PSA effects, sexual side effects and combination therapy — belongs to the BPH chapter.

Helping the sphincter: stress incontinence

The third failure is a weak outlet during storage: with a poorly supported urethra or a lax sphincter, a cough or a sneeze raises abdominal pressure above what the sphincter can hold, and urine leaks — stress urinary incontinence. Here the aim is the opposite of BPH: strengthen the sphincter, not relax it. The pharmacological lever is the pudendal (somatic) nerve to the external sphincter, which is potentiated by serotonin and noradrenaline in the spinal cord; duloxetine, a serotonin–noradrenaline reuptake inhibitor, raises sphincter tone during filling and can reduce leakage. It is an adjunct rather than a cure — pelvic-floor exercises remain first-line — but it shows the diagram running the other way: reinforce the somatic hold instead of releasing an outlet.